The Impact of Dosimeter on Measurement of Airway Responsiveness to Methacholine
Asthma

About this trial
This is an interventional diagnostic trial for Asthma focused on measuring methacholine PC20, dosimeter, asthma
Eligibility Criteria
Inclusion Criteria: Non-smoking male or female >18 years of age, with a previous diagnosis of asthma. Women of child bearing age must not be pregnant or nursing and be using an acceptable method of contraception. Screening FEV1 > 70% of predicted for height, age, sex, and race when bronchodilators are withheld for appropriate intervals. At least a 20% decrease in FEV1 after inhaling ≤ 8 mg/ml of methacholine (i.e., a PC20 FEV1 ≤8 mg/ml) using the KoKo Digidoser system. Ability to perform ATS-acceptable and reproducible spirometry. Exclusion Criteria: Cigarette smoking in past year or > 10 pack year smoking history. Respiratory tract infection within the last four weeks. History of severe asthma attack requiring hospitalization in the previous 12 months. Short course of oral corticosteroids in the past 3 weeks. Inability to withhold caffeinated beverages for 12 hours or medications for appropriate intervals prior to each methacholine challenge. If female, a positive urine β-HCG test.
Sites / Locations
- University of Florida Asthma Research Lab